sphingotec is a biomarker company that develops and commercializes innovative biomarkers for the diagnosis and monitoring of various medical conditions.

sphingotec

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies.

SphingoTec GmbH was established in 2002 by Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).


HBM Healthcare Investments AG

EASME - EU Executive Agency for SMEs

Brandenburg Kapital

Wellington Partners

HBM Partners

SphingoTec

SphingoTec has successfully secured funding to drive its global expansion, including the US market, through strategic collaborations.
The investment round is led by Think. Health Ventures, with support from existing investors. Think. Health Ventures will add significant value to SphingoTec through its expertise in diagnostics and its extensive network in clinics and laboratories.
The raised capital will be pivotal in advancing the out-licensing and commercialization of SphingoTec’s innovative biomarkers for critical care, aiming to significantly improve patient management and outcomes.
The funding underscores SphingoTec’s dedication to pioneering advancements in critical care patient management. 

👉Read the press release here www.sphingotec.com

#SeriesC #Financing #Diagnostics #Innovations

Despite the slow progress in #sepsis #biomarker innovations, encouraging evidence is emerging. As technology and understanding of sepsis pathophysiology continue to evolve, biomarkers like sTREM-1, bio-adrenomedullin, or monocyte expression of HLA-DR are showing very promising associations with particular pathophysiological mechanisms. 

🔬These advancements in biomarker research are poised to revolutionize sepsis management through personalized approaches, ultimately improving patient outcomes and reducing the burden of this life-threatening condition.

📰 The following review discusses key considerations from public and private perspectives on enhancing sepsis biomarker development. Read more in this latest review paper: https://rdcu.be/dPFo7

The #ADLM2024 in Chicago, the world's premier gathering for clinical laboratory professionals, is approaching and SphingoTec is looking forward to participating. Our managing directors Deborah Bergmann, and Florian Uhle will be attending to engage with industry leaders, stay informed on the latest trends in laboratory medicine, and learn from the best in the industry.

Part of our strategy this year is expanding the global reach of our biomarker innovations while focusing on enhancing patient care and addressing unmet clinical needs. To achieve this, we are forging strategic collaborations and exchanging ideas with industry leaders.

Are you attending ADLM 2024? We'd love to connect! Reach out to schedule a meeting with our team: event@sphingotec.com
#LabMedicineInnovation #StrategicPartnerships

A precise assessment of kidney function is crucial in modern intensive care. Traditional methods like Serum Creatinine (SCr) and estimated Glomerular Filtration Rate (eGFR) have limitations, especially in acute kidney injury (AKI) diagnosis. 

Proenkephalin A 119-159 (#penKid), an innovative biomarker, offers a promising alternative. Unlike traditional markers, penKid is unaffected by gender, muscle mass, or inflammation and correlates well with measured GFR. Scientists have developed a new eGFR formula based on penKid, creatinine, and age, providing superior accuracy. Early identification of subclinical AKI and recovery monitoring make penKid a promising tool for personalized therapy planning. 

For more information, read the full article on page 6: 
https://lnkd.in/dEVSEKQT

#Healthcare #KidneyHealth #MedicalInnovation

Congratulations to our partner company Adrenomed AG for receiving their FDA fast-track designation to #Enibarcimab. In this precision medicine approach addressing septic shock patients, #SphingoTec’s biomarker bioactive adrenomedullin (bio-ADM) has been included in the biomarker-guided Phase II clinical trial to support enrichment of the patient population benefitting most from Enibarcimab. We look forward to continuing the collaboration and jointly enabling precision medicine for critically ill patients. 

#SepticShock #FDA #bioADM #precisionmedicine #ICU #biomarkers

Professor Claudio Ronco and Deborah Bergmann, CEO of Sphingotec, recently discussed the latest developments of the biomarker penKid during the "Cappuccino with Claudio Ronco" series, which is marking its 10th anniversary. This discussion was filmed at the Vicenza Course in Italy.

Their conversation focused on penKid's added value in identifying subclinical AKI and potentially supporting the identification of windows of opportunity in the treatment and management of AKI.

https://lnkd.in/diMpZEi8

#MedicalInnovation #Nephrology #CriticalCare #PenKid #VicenzaCourse #HealthcareAdvancements

COM:SPHINGOTEC

sphingotec

Financials Not Available